Sebastien Latapie Promoted to Partner at AVANT BIO
"The enabling technologies emerging at the intersection of technology and life sciences represent a massive opportunity to fundamentally change how we discover, develop, and deliver breakthrough therapies," said
Since joining AVANT BIO,
"Sebastien has been an integral part of AVANT BIO's journey, demonstrating exceptional vision and leadership in identifying and nurturing new groundbreaking opportunities in the sector. Sebastien's promotion to Partner is not only a testament to his accomplishments but also a significant step forward as we continue to scale our mission of transforming therapeutic enabling technologies," stated
About AVANT BIO
AVANT BIO is a growth equity firm focused on the enabling technologies shaping how tomorrow's therapeutics are developed, with an investment focus that accelerates new growth and innovation at various stages of company development. With a commitment to amplifying value and a forward-looking investment strategy, AVANT BIO is primed to unlock the full potential of therapeutic enabling technologies, TechBio, and Healthtech. With over eight decades of experience combined across our team, we provide connections, deep expertise, and long-term guidance to bring innovative ideas to life and drive transformative technologies. More information can be found at www.avant.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/sebastien-latapie-promoted-to-partner-at-avant-bio-302348646.html
SOURCE AVANT BIO LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Indotek Group acquires remaining 53% stake in Auchan Hungary, assumes full ownership
- Oxford Advisory Group Examines Roth Conversions and Tax Strategies for Retirement
- FP Markets expands its share CFD portfolio with landmark SpaceX (SPCX) listing
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share